Clinical Trials
26 trialsVenetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
Dana-Farber Cancer Institute
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
M.D. Anderson Cancer Center
A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL
Georgetown University
CIML NK Cells With Venetoclax for AML
Dana-Farber Cancer Institute
Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker
The Methodist Hospital Research Institute
Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies
University of Alabama at Birmingham
CAVALRY
University of Chicago
GAVEL
Dana-Farber Cancer Institute
Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia
Columbia University
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
Children's Hospital Medical Center, Cincinnati
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
Dana-Farber Cancer Institute
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
Dana-Farber Cancer Institute
Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia
University of Colorado, Denver
Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL
Swiss Cancer Institute
Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL
M.D. Anderson Cancer Center
HEM-iSMART C
Princess Maxima Center for Pediatric Oncology
HEM-iSMART B
Princess Maxima Center for Pediatric Oncology
HEM-iSMART E
Princess Maxima Center for Pediatric Oncology
SEVENAZA
Gustave Roussy, Cancer Campus, Grand Paris
Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Jonsson Comprehensive Cancer Center
Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in Italy
Gruppo Italiano Malattie EMatologiche dell'Adulto
Venetoclax Combined with Intensive Therapy for Acute Myeloid Leukemia Patients with Lower Early Peripheral Blast Clearance Rate After Standard Induction Therapy
Affiliated Hospital of Nantong University
HEM-iSMART A
Princess Maxima Center for Pediatric Oncology
PAVE
Medical College of Wisconsin